Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer. Issue 5 (September 2018)

• Record Type: Journal Article
• Authors: Sabatier, Renaud; Nicolas, Emanuel; Paciencia, Maria; Jonville-Béra, Annie-Pierre; Madroszyk, Anne; Cecile, Maud; Braticevic, Cecile; Duran, Ségolène; Tassy, Louis; Rouby, Franck; Micallef, Joëlle; Rousseau, Frédérique
• Is Part Of: Journal of geriatric oncology. Volume 9:Issue 5(2018)
• Page Start: 494
• Page End: 500
• Publication Date: 2018-09
• Subjects: NSCLC non-small cell lung cancer -- IrAE immune-related adverse event -- PFS progression-free survival -- OS overall survival -- CMI Charlson's comorbidity index -- ECOG Eastern Cooperative Oncology Group -- ADR adverse drug reaction -- SAE serious adverse event -- FFPE formalin-fixed paraffin-embedded; Metastatic non-small cell lung cancer -- Nivolumab -- Older patients -- Safety -- Pharmacovigilance; Geriatric oncology -- Periodicals; Neoplasms -- Periodicals; Aged -- Periodicals; Geriatric oncology; Electronic journals; Periodicals; 618.976994005
• DOI: 10.1016/j.jgo.2018.02.011
• Languages: English
• ISSNs: 1879-4068

Abstract

Abstract: Background: Nivolumab is approved worldwide as second-line treatment for metastatic non-small cell lung cancer (NSCLC). Despite the fact that most of these cancers are being diagnosed in the older patients, few of the patients were included in pivotal trials. We aimed to describe efficacy and safety in a "real-world" older population. Patients and Methods: We retrospectively collected data from older patients (≥70 years old) with advanced or metastatic NSCLC treated with Nivolumab in our institution. We analyzed safety (CTCAE v4.0 criteria), efficacy (clinical benefit rate, progression-free survival, and overall survival), and correlated these features to geriatric parameters and PD-L1 expression. Along with this cohort, we assessed safety at a national level by retrieving all cases of Nivolumab (prescribed for NSCLC) induced adverse events analyzed by the French pharmacovigilance network during the inclusion period. Results: From July 2015 to September 2016, 30 patients were enrolled with a median age of 75.2. Clinical benefit rate was 30.6%. Median progression-free survival and overall survival were 3.3 and 7.1 months, respectively. Fifteen patients (50%) presented an immune-related adverse event (IrAE) of any grade, including four high grade IrAEs. Two hundred and eighty IrAEs had been notified to the French pharmacovigilance network including 91 (35.2%) concerning older patients. Frequency and pattern of IrAEs were similar for older patients and younger subjects. Conclusions: Even though frequency and patterns of IrAEs are different from pivotal studies, these results don't seem specific to older patients. Further prospective investigations are needed to better characterize and predict the impact of Nivolumab on older patients with NSCLC.